Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: does age really matter?

Non-small cell lung cancer (NSCLC) is a disease predominantly reported in older adults. A recent analysis from the Surveillance Epidemiology End Result (SEER) database reported that 50% of lung cancers are diagnosed in people aged more than 70 years and 15% are diagnosed in patients older than 80 [1]. Currently, the highest mortality rate is seen in these age groups [1], due to decreased physiologic reserve, reduced benefit of cancer treatment and increased risks of iatrogenic toxicities and death.

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2v7PbEz
via IFTTT